Gilead Sciences
$144.74Change from previous close: −1.87%Absolute change: −$2.76
At a glance
- Revenue growth
- +2.40%
- 2025 vs 2024
- Net income growth
- +1,672.92%
- 2025 vs 2024
- Net margin
- 28.9%
- 2024: 1.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 10,019 | 10,828 | 8,006 | 9,072 | 11,384 |
| Depreciation and amortization | 2,760 | 2,767 | 2,693 | 2,103 | 2,050 |
| Capital expenditure | -563 | -523 | -585 | -728 | -579 |
| Investing cash flow | -4,793 | -3,449 | -2,265 | -2,466 | -3,131 |
| Financing cash flow | -7,745 | -3,433 | -5,125 | -6,469 | -8,877 |
| Dividends paid | -4,003 | -3,918 | -3,809 | -3,709 | -3,605 |
| Share repurchases | -1,922 | -1,150 | -1,000 | -1,396 | -546 |
| Debt issued | 0.0 | 3,464 | 1,980 | 0.0 | — |
| Debt repaid | -1,788 | -1,970 | -2,250 | -1,500 | — |
| Effect of exchange rates | 92.0 | -40.0 | 57.0 | -63.0 | -35.0 |
| Net change in cash | -2,427 | 3,906 | 673 | 74.0 | -659 |
| Free cash flow | 9,456 | 10,305 | 7,421 | 8,344 | 10,805 |
| Levered free cash flow | 7,541 | 10,131 | 8,497 | 6,935 | 10,203 |